At present, due to the limited species specificity of available complement inhibitors such as pegcetacoplan, which primarily targets complement of humans and non-human primates (70, 71), there are no comparable data that allow us to assess the rate at which C3 deposits are removed from the kidneys in the FH–/– mouse model. Here, C3 is linked to familial hyperaldosteronism.